EYEN - アイノビア （Eyenovia Inc.）

Eyenovia is stepping up the capabilities of its facilities and taking advantage of the thriving innovation culture and expertise in Reno, Nevada, and Redwood City, CaliforniaNEW YORK, NY / ACCESSWI…

Eyenovia is stepping up the capabilities of its facilities and taking advantage of the thriving innovation culture and expertise in Reno, Nevada, and Redwood City, California NEW YORK, NY / ACCESSWIRE / June 6, 2023 / Eyenovia, Inc. (NASDAQ:EYEN), an ophthalmic technology company commercializing and developing the Optejet® device for use both in connection with its own mydriasis product and product candidates for presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, is proud to announce the expansion of its U.S. manufacturing facilities in Redwood City, California, and Reno, Nevada. The Bay Area is known for its thriving biotech industry , and in Reno, the medical device and technology sectors are booming in part due to having the largest industrial park in the world, which are some of the driving factors behind Eyenovia''s expansion plans. The Redwood City facility, which was announced operational last year, focuses primarily on Optejet® pharmaceutical manufacturing finishing operations, including drug loading, labeling, and packaging prior to distribution.

FDA gave approval of their first drug on May 8th, 2023. The company is now finalizing its drug launch in the coming months. Click here to read more on EYEN stock.

Eyenovia, Inc. (NASDAQ:NASDAQ:EYEN) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ETCompany ParticipantsJohn Gandolfo - CFO & SecretaryMichael Rowe - CEO & DirectorBren Kern…

Eyenovia (NASDAQ: EYEN ) reported its Q1 earnings results on Thursday, May 11, 2023 at 04:05 PM. Here''s what investors need to know about the announcement. Earnings Eyenovia beat estimated earnings by 21.05%, reporting an EPS … Full story available on Benzinga.com

NEW YORK, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN ), a pre-commercial ophthalmic technology company developing the Optejet ® delivery system for use both in connection with its own drug-device therapeutic programs for mydriasis, presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, today announced that Stephen Benjamin, an independent director on the Company''s Board of Directors, is stepping down to assume the role of Head of the White House''s Office of Public Engagement. Mr. Benjamin, an attorney, former three-term mayor of Columbia, South Carolina and 76 th President of the U.S. Conference of Mayors, with an extensive record of achievement in government and the public sector, joined the Eyenovia Board in February 2022. "We are beyond thrilled for Stephen, and wish him all the best in this important and high-profile role within the President''s administration," stated Michael Rowe, Chief Executive Officer of Eyenovia. "Over the past year, Steve Benjamin''s insights and guidance have served us well at Eyenovia, and it is due in part to his service that we have achieved so much during that time." Eyenovia''s Board will continue to consist of seven members.

NEW YORK, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet ® delivery system for use both in connection with its own drug-device therapeutic programs for mydriasis, presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, today announced that Stephen Benjamin, an independent director on the Company’s Board of Directors, is stepping down to assume the role of Head of the White House’s Office of Public Engagement.

I will update my previous two articles about Eyenovia. NDA accepted with no outside advisory committee formed to review their submission. Read more here.

https://www.investing.com/news/assorted/eyenovia-inc-announces-development-collaboration-agreement-with-formosa-pharmaceuticals-432SI-3004274

Collaboration will combine Eyenovia’s Optejet® dispensing technology with Formosa’s APNT™ nanoparticle formulation platform for the potential development of new topical therapeutics in high-value ophthalmic indications with significant unmet medical needs. Collaboration will combine Eyenovia’s Optejet® dispensing technology with Formosa’s APNT™ nanoparticle formulation platform for the potential development of new topical therapeutics in high-value ophthalmic indications with significant unmet medical needs.

Eyenovia press release (EYEN): Q4 GAAP EPS of $0.10 beats by $0.32.Revenue of $10M (+400.0% Y/Y).As of December 31, 2021, the Company’s cash and cash equivalents were approximately…

Successfully completed Type A meeting with FDA and anticipates MydCombi™ NDA resubmission in Q3 2022

Eyenovia Inc (NASDAQ: EYEN ) has entered into a Securities Purchase Agreement with Armistice Capital Master Fund Ltd for gross proceeds of $15 million . The offering includes 3 million shares, pre-funded warrants to purchase up to 1.87 million shares, and common warrants to purchase up to 4.87 million shares. The aggregate offering price for each share of … Full story available on Benzinga.com

Eyenovia (EYEN) trades 2.3% down premarket after it entered into a securities purchase agreement with Armistice Capital Master Fund in an offering of 3M shares of its common…